Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Matthay

Showing results (311-320 of 316) with videos related to

Pageof 32
Sort By:
You have reached the last page of results.This site can display upto 316 results.
European Journal of Cancer (Oxford, England : 1990)|March 28, 1998
The International Neuroblastoma Risk Groups (INRG): a preliminary reportR P Castleberry, J Pritchard, P Ambros, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2018
Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory NeuroblastomaSteven G DuBois, Yael P Mosse, Elizabeth Fox, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2021
Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT ConsortiumSteven G DuBois, M Meaghan Granger, Susan Groshen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 23, 2025
Phase I Study of <sup>131</sup>I-Metaiodobenzylguanidine With Dinutuximab ± Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy TrialThomas Cash, Araz Marachelian, Steven G DuBois, et al.
Journal of the National Cancer Institute|August 25, 2025
International neuroblastoma risk group consortium: a model of a networking for rare cancersSusan L Cohn, Wendy B London, Gudrun Schleiermacher, et al.
Nature Medicine|April 3, 2023
Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial resultsKelly C Goldsmith, Julie R Park, Kimberly Kayser, et al.
Pageof 32

Showing results (311-320 of 316) with videos related to

Sort By:
Pageof 32
You have reached the last page of results.This site can display upto 316 results.
European Journal of Cancer (Oxford, England : 1990)|March 28, 1998
The International Neuroblastoma Risk Groups (INRG): a preliminary reportR P Castleberry, J Pritchard, P Ambros, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2018
Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory NeuroblastomaSteven G DuBois, Yael P Mosse, Elizabeth Fox, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2021
Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT ConsortiumSteven G DuBois, M Meaghan Granger, Susan Groshen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 23, 2025
Phase I Study of <sup>131</sup>I-Metaiodobenzylguanidine With Dinutuximab ± Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy TrialThomas Cash, Araz Marachelian, Steven G DuBois, et al.
Journal of the National Cancer Institute|August 25, 2025
International neuroblastoma risk group consortium: a model of a networking for rare cancersSusan L Cohn, Wendy B London, Gudrun Schleiermacher, et al.
Nature Medicine|April 3, 2023
Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial resultsKelly C Goldsmith, Julie R Park, Kimberly Kayser, et al.
Pageof 32